PR Newswire BiotechOriginal article
Remepy Welcomes Pharma R&D Leader, Eran Harary, MD, as Chief Medical Officer, to Advance Hybrid Drug™ Pipeline
Phase 3Hybrid Drug™Positive
AI Analysis
Summary
Remepy appoints Eran Harary, MD, former Teva SVP of R&D, as Chief Medical Officer to lead advancement of its Hybrid Drug™ for Parkinson's disease as the company prepares to commence Phase III trials and expand its pipeline.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Preparing to commence Phase III
Importance:5/10
Sentiment:
0.30
management appointmentPhase 3 initiationParkinson's diseasepipeline expansion
Related Companies
Read the original article
Published by PR Newswire Biotech on September 16, 2026 11:30 AM